The current news roundup on Bio-Rad Laboratories presents a mixed view in terms of its stock performance and overall business outlook. While analysts suggest the company is undervalued, especially with its reduced debt and price drop, there is some weakness with a reported three-year loss of 61% and a decrease in performance this quarter. Despite these, there has been investor interest with First Pacific Advisors adding 214,705 shares of Bio-Rad to their portfolio and Zacks Research having a positive outlook of their FY2027 earnings.
Items that may impact the stock value include the move to acquire Stilla, securing $29.1 million in funding led by Bio-Rad to advance transplant diagnostics, and missed Q4 earnings. The COO, Jon DiVincenzo headlined the Jefferies Healthcare conference suggesting strategic focus amidst challenges. Bio-Rad's stake in Sartorius was highlighted as driving long-term value, but its reliance on the bio-tech market could prove risky with a cut in revenue forecast due to weak biotech demand.
Bio-Rad Laboratories Stocks News Analytics from Mon, 09 Nov 2015 08:00:00 GMT to Sat, 21 Jun 2025 16:38:00 GMT - Rating -3 - Innovation -1 - Information 8 - Rumor -6
